Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

FDA Approves Ranabxy’s Donepezil 5 mg and 10 mg Tablets

By Pharmaceutical Processing | November 30, 2010

Ranbaxy Pharmaceuticals Inc. has received final approval
from the FDA to manufacture and market Donepezil
Hydrochloride Tablets 5 mg and 10 mg with 180-day market exclusivity in the U.S. healthcare
system. Total annual market sales for Aricept 5 mg and 10 mg tablets were $2.6
billion (IMS-MAT: September 2010). Aricept is indicated for the treatment of
dementia of the Alzheimer’s type, and in patients with mild to moderate and severe
Alzheimer’s disease.

“We are pleased to announce the launch of Donepezil,
which expands Ranbaxy’s portfolio of affordable generic pharmaceuticals.
Ranbaxy’s generic formulation of Aricept will benefit the U.S. healthcare system by providing a more
affordable treatment option to patients, which will have a positive impact on
escalating U.S.
healthcare costs,” said Bill Winter, Vice President of Trade Sales, RPI.

According to the Alzheimer’s Association, 5.3 million
Americans of all ages have Alzheimer’s disease. “Since the incidence of
dementia has increased, while the costs associated with treating dementia
continue to rise, the launch of a generic formulation of Donepezil tablets will
provide patients with a cost effective alternative. The end result will be a
significant reduction in healthcare costs for those individuals suffering from
Alzheimer’s disease,” commented Arun Sawhney, Managing Director, Ranbaxy
Laboratories Ltd.

Related Articles Read More >

FDA logo
Ultra Supplement announces recall for undeclared tadalafil
analyzing medical sample
Expert answers to nitrosamine impurity questions
Cardinal Health
Cardinal Health announces $124M settlement of investors’ opioid suit
FDA logo
FDA warns four companies over selling honey tainted with prescription drugs

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards